ETFS Holding Cubist Pharmaceuticals, Inc.

 
News Articles for Cubist Pharmaceuticals, Inc. top ^
2014/12/10
Levi & Korsinsky is investigating the Board of Directors of Cubist Pharmaceuticals, Inc. (“Cubist Pharmaceuticals” or “the Company”) (NasdaqGS:CBST) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Merck & Co.
Sign-up for CBST SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces Investigation of the Board of Directors of Cubist Pharmaceuticals, Inc. Regarding the Fairness of the Sale of the Company to Merck & Co. investment picks
2014/12/9
SAN DIEGO and LEXINGTON, Mass.
Sign-up for Acquisition of Cubist Pharmaceuticals, Inc. (CBST) by Merck & Co., Inc. (MRK) May Not Be in Shareholders' Best Interests investment picks
2014/12/9
WAYNE, Pa.
Sign-up for Ryan & Maniskas, LLP Announces Investigation of Cubist Pharmaceuticals Inc. investment picks
2014/12/8
NEW YORK , Dec.
Sign-up for Harwood Feffer LLP Announces Investigation of Cubist Pharmaceuticals Inc. investment picks
2014/12/8
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Cubist Pharmaceuticals, Inc. (“Cubist” or the “Company”) (Nasdaq: CBST) relating to the proposed buyout of the Company by Merck & Co., Inc. (“Merck”). On December 8, 2014, Cubist and Merck announced the signing of a definitive agreement pursuant to which Merck will acquire Cubist in a transaction valued at approximately $9.5 billion.
Sign-up for SHAREHOLDER ALERT: Brower Piven Launches An Investigation Into The Proposed Sale Of Cubist Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm For Additional Information investment picks
2014/12/8
Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of Cubist Pharmaceuticals, Inc. (“Cubist”) (NASDAQ GS:CBST) concerning the sale to Merck & Co., Inc. Under the terms of the agreement, Cubist shareholders will receive $102.00 in cash for each share owned, which is only a 37% premium over the share price just before the deal was announced and only a slight premium over the 52-week high.
Sign-up for CUBIST PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe and Powers Taylor LLP Investigate Sale to Merck & Co., Inc. investment picks
2014/12/8
WILMINGTON, Del.
Sign-up for CUBIST PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout investment picks
2014/12/8
Shareholder Rights Law Firm Johnson & Weaver, LLP is investigating whether members of the board of directors of Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) breached their fiduciary duties in connection with the planned merger of the Company with Merck & Co., Inc. Cubist is engaged in the research, development, and commercialization of pharmaceutical products for medical needs in the acute care environment.
Sign-up for CUBIST PHARMACEUTICALS ALERT: Johnson & Weaver, LLP Investigates the Fairness of Price and Process in Proposed Sale of Cubist Pharmaceuticals, Inc. to Merck investment picks
2014/12/8
By Peter Loftus and Dana CimillucaThe per-share bid of $102 is 37% above Friday's closing price of Cubist's stock Drug giant Merck & Co.
Sign-up for Merck to buy Cubist Pharmaceuticals for $8.4 billion investment picks
2014/12/8
Cubist Pharmaceuticals (CBST) announced on Monday an agreement to be acquired by Merck & Co.
Sign-up for Merck to buy Cubist Pharmaceuticals in $9.5 billion deal investment picks
2014/12/8
Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Cubist Pharmaceuticals, Inc. (NASDAQ:CBST) today announced that the companies have entered into a definitive agreement under which Merck will acquire Cubist for $102 per share in cash, which represents a 35 percent premium to Cubist’s average stock price for the most recent five trading days.
Sign-up for Merck to Acquire Cubist Pharmaceuticals for $102 Per Share in Cash investment picks
2014/12/12
Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Cubist Pharmaceuticals NEW YORK , Dec.
Sign-up for CUBIST PHARMACEUTICALS INVESTOR ALERT: Faruqi & Faruqi, LLP Announces the Investigation of Cubist Pharmaceuticals, Inc. Over the Proposed Sale of the Company to Merck & Co. Inc. - CBST investment picks
2014/12/12
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Cubist Pharmaceuticals, Inc. (“Cubist” or the “Company”) (Nasdaq: CBST) relating to the proposed buyout of the Company by Merck & Co., Inc. (“Merck”). On December 8, 2014, Cubist and Merck announced the signing of a definitive agreement pursuant to which Merck will acquire Cubist in a transaction valued at approximately $9.5 billion.
Sign-up for SHAREHOLDER ALERT: Brower Piven Launches An Investigation Into The Proposed Sale Of Cubist Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm For Additional Information investment picks
2014/12/12
The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of Cubist Pharmaceuticals, Inc. (NasdaqGS: CBST) (“Cubist”) in connection with the sale of the Company to Merck & Co.
Sign-up for CBST SHAREHOLDER ALERT: The Law Offices of Vincent Wong Launches Investigation of the Board of Directors of Cubist Pharmaceuticals, Inc. in Connection With the Fairness of the Sale of the Company to Merck & Co. investment picks
2014/12/11
Rigrodsky & Long, P.A.: Do you own shares of Cubist Pharmaceuticals, Inc. (NASDAQ GS: CBST )? Did you purchase any of your shares prior to December 8, 2014?
Sign-up for CUBIST PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout investment picks

Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

ETFS Holding Cubist Pharmaceuticals, Inc.
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: ETFS Holding Cubesmart  |  Next: ETFS Holding Cummins Inc